However, concurrent treatment of tumor-bearing mice with pE7+pIL-2+anti-4-1BB Abs resulted in significantly higher therapeutic antitumor activity compared to treatment with pE7+pcDNA3. The gene discussed is TNFRSF9; the disease is neoplasm.